A Systematic Review of Treatments for Relapsed/Refractory Mantle Cell Lymphoma

A systematic literature review was conducted to evaluate the clinical effectiveness and safety of treatments for patients with relapsed/refractory mantle cell lymphoma (MCL) unsuitable for intensive treatment. Criteria for inclusion of trials were established prior to the literature review. A search of Medline, Embase and the Cochrane library databases was conducted to identify phase II or III randomised controlled trials (RCTs), published from January 1st 1994 to 29th May 2016. Relevant conference abstracts, citation lists from included articles, published guidelines and on-going clinical trial databases were also searched.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research

Related Links:

Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Source Type: research
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Source Type: research
In the last few months two main streams of research have dominated the panorama of myelodysplastic syndrome investigations: one deepening the insight into pathogenic role, hierarchy and prognostic impact of somatic mutations and, as a consequence, into the impact of inherited congenital predisposing conditions; the second, quite interlinked in fact to the first one, analysing inflammation and innate immunity in myelodysplastic syndrome patients. The research devoted to clarifying mechanisms of action and mechanisms of resistance to hypomethylating agents has also advanced, mostly because of different approaches to the stud...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research
The widespread adoption of Bcr-Abl-directed tyrosine kinase inhibitors (TKIs) into frontline regimens for patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) has revolutionized the outcomes of patients with this disease. Whereas Ph+ ALL was historically associated with cure rates of less than 25% in the pre-TKI era, now long-term survival in more than 75% of patients has been reported. With the promising efficacy of later-generation TKIs (e.g. ponatinib) and the emerging understanding of the prognostic significance of various cooperative genomic alterations and of minimal residual diseas...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research
Chronic myelomonocytic leukemia (CMML) is a relatively uncommon hematologic malignancy that manifests as peripheral monocytosis, varying degrees of bone marrow dysplasia, and is associated with poor outcomes. Despite growing appreciation of the pathobiological mechanisms driving CMML, current therapies have not clearly demonstrated survival benefit. The complex pathobiology of CMML highlights the intricate aberrantly activated cellular pathways that influence disease phenotype and limit current treatment options.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research
HIV- associated lymphomas (HAL) remain an important cause of morbidity and mortality in HIV patients, especially in the refractory setting. Hematopoietic cell transplantation (HCT) is considered a curative option for patients with refractory HAL.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Combination regimens with anti-CD20 agents may improve outcomes of patients with relapsed or refractory B-cell malignancies, but comparative clinical evidence is limited. This review assessed the published evidence on the efficacy of anti-CD20 monoclonal antibodies in combination with chemotherapy in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), or diffuse large B-cell lymphoma (DLBCL), using a rapid evidence assessment (REA) approach. MEDLINE ®, Embase® and the Cochrane Library were searched from January 1, 1997 to July 14, 2017 (English language only).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research
A safety profile of medications used to treat Waldenström's macroglobulinemia. Expert Opin Drug Saf. 2018 May 17;: Authors: García-Sanz R, Jiménez C, González de la Calle V, Sarasquete ME Abstract INTRODUCTION: Waldenström's macroglobulinemia (WM) is a B-cell lymphoproliferative disease with serum IgM monoclonal component and bone marrow infiltration by lymphoplasmacytic lymphoma. Traditional therapy was based on that regimens used for closely related entities, such as chronic lymphocytic leukemia or multiple myeloma. This resulted in a lack of drugs specifically approved...
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research
Conditions:   Multiple Myeloma;   CLL;   Chronic Lymphocytic Leukemia;   Lymphoma Interventions:   Radiation: Total Body Irradiation;   Procedure: Haploidentical Stem Cell Transplantation;   Biological: CD56-Enriched Donor Lymphocyte Infusion;   Drug: Bendamustine;   Drug: Fludarabine;   Drug: Rituximab Sponsors:   Noah Merin;   Miltenyi Biotec GmbH;   TEVA Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Clinical Trials | Conferences | Databases & Libraries | Hematology | Leukemia | Lymphoma | Myeloma